MDX H210Alternative Names: MDX-H210
Latest Information Update: 03 May 2007
At a glance
- Originator Medarex
- Class Bispecific antibodies; Monoclonal antibodies
- Mechanism of Action ERBB 2 receptor antagonists; IgG receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Breast cancer; Prostate cancer